The EPS miss and widening net loss reinforce the bearish thesis, but the sNDA acceptance and strategic review create a binary catalyst by November 2026. Traders should watch for any financing announcement (dilutive) or M&A deal (potentially positive) as the cash runway is limited. The stock is likely to trade on the strategic review outcome and PDUFA date rather than quarterly fundamentals.
Price Chart
Executive Summary
BioXcel Therapeutics reported Q1 2026 EPS of -$0.54 (GAAP) vs consensus -$0.48, a -12.5% miss, with IGALMI revenue of $206K. The FDA accepted the sNDA for at-home IGALMI use with a November 14, 2026 PDUFA date, and the company is exploring strategic options including a potential sale. Net loss widened to $12.7M from $7.3M a year ago, with cash of $17.2M raising going-concern risk.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP EPS -$0.54 vs consensus -$0.48 (miss of 12.5%)
- Q1 2026 revenue $206K, up from $168K YoY but minimal
- Net loss $12.7M vs $7.3M YoY, driven by higher interest and SG&A
- Cash and equivalents $17.2M, down from $28.8M at year-end 2025
- FDA accepted sNDA for at-home IGALMI use; PDUFA date Nov 14, 2026
- Company engaged MTS Health Partners to explore strategic options including sale
- Operating loss $10.2M, essentially flat YoY
- Weighted average shares outstanding surged to 23.6M from 4.8M YoY due to dilution
Financial Impact
EPS miss of 12.5% vs consensus; net loss widened 75% YoY to $12.7M; cash burn rate implies runway < 6 quarters without additional financing
Risk Factors
- Cash runway of $17.2M may require dilutive financing before PDUFA date
- sNDA approval not guaranteed; FDA could issue CRL
- Strategic review may not result in a favorable transaction
- Going-concern risk if no deal or financing materializes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295725 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 7w ago | 8-K | $0.1370 | awaiting T+60 | — | — |
Aug 28, 2026 8w ago | Press Release | $0.1814 | awaiting T+60 | — | — |
Aug 25, 2026 8w ago | 8-K | $0.7422 | awaiting T+60 | — | — |
Aug 11, 2026 10w ago | 8-K | $0.9320 | awaiting T+60 | — | — |
Aug 3, 2026 12w ago | 8-K | $0.8480 | awaiting T+60 | — | — |
Jul 6, 2026 16w ago | 8-K | $1.10 | awaiting T+60 | — | — |
May 22, 2026 22w ago | Insider Cluster | $1.22 $0.8274 | ▲ +32.18% | ▲ +34.91% | — |
May 20, 2026 22w ago | 144 | $1.14 $0.8900 | ▼ −21.93% | ▼ −26.23% | — |
May 15, 2026 23w ago | 8-K | $1.14 $0.9319 | ▼ −18.25% | ▼ −22.77% | — |
May 15, 2026 23w ago | Press Release | $1.14 $0.9319 | ▲ +18.25% | ▲ +22.77% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers